{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,2]],"date-time":"2025-08-02T14:27:59Z","timestamp":1754144879645,"version":"3.41.2"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,7,15]]},"DOI":"10.7759\/cureus.88037","type":"journal-article","created":{"date-parts":[[2025,7,16]],"date-time":"2025-07-16T04:14:28Z","timestamp":1752639268000},"source":"Crossref","is-referenced-by-count":0,"title":["Real-World Evaluation of the Dosage Patterns and Safety of Angiotensin Receptor-Neprilysin Inhibitor Therapy in Indian Patients With Heart Failure With Reduced Ejection Fraction: The ADD-ARNI Study Protocol"],"prefix":"10.7759","author":[{"given":"Sanjay","family":"Mittal","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashwani","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kamal","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P B","family":"Jayagopal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arindam","family":"Pande","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amarnath","family":"Sugumaran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandesh","family":"Sawant","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Senthilnathan","family":"Mohanasundaram","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.122.027852","article-title":"Burden, trends, and inequalities of heart failure globally, 1990 to 2019: a secondary analysis based on the Global Burden of Disease 2019 study","volume":"12","author":"Yan T","year":"2023","unstructured":"Yan T, Zhu S, Yin X, et al.. Burden, trends, and inequalities of heart failure globally, 1990 to 2019: a secondary analysis based on the Global Burden of Disease 2019 study. J Am Heart Assoc. 2023, 12:e027852. 10.1161\/JAHA.122.027852","journal-title":"J Am Heart Assoc"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1002\/ehf2.14096","article-title":"Clinical profile and 90 day outcomes of 10 851 heart failure patients across India: National Heart Failure Registry","volume":"9","author":"Harikrishnan S","year":"2022","unstructured":"Harikrishnan S, Bahl A, Roy A, et al.. Clinical profile and 90 day outcomes of 10 851 heart failure patients across India: National Heart Failure Registry. ESC Heart Fail. 2022, 9:3898-908. 10.1002\/ehf2.14096","journal-title":"ESC Heart Fail"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1007\/s40119-023-00323-8","article-title":"Practical recommendations for the use of angiotensin receptor-neprilysin inhibitors (ARNI) in heart failure: insights from Indian cardiologists","volume":"12","author":"Dalal J","year":"2023","unstructured":"Dalal J, Chandra P, Ray S, et al.. Practical recommendations for the use of angiotensin receptor-neprilysin inhibitors (ARNI) in heart failure: insights from Indian cardiologists. Cardiol Ther. 2023, 12:445-71. 10.1007\/s40119-023-00323-8","journal-title":"Cardiol Ther"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1002\/ehf2.13646","article-title":"'Time is prognosis' in heart failure: time-to-treatment initiation as a modifiable risk factor","volume":"8","author":"Abdin A","year":"2021","unstructured":"Abdin A, Anker SD, Butler J, et al.. 'Time is prognosis' in heart failure: time-to-treatment initiation as a modifiable risk factor. ESC Heart Fail. 2021, 8:4444-53. 10.1002\/ehf2.13646","journal-title":"ESC Heart Fail"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1093\/cvr\/cvac013","article-title":"Global burden of heart failure: a comprehensive and updated review of epidemiology","volume":"118","author":"Savarese G","year":"2023","unstructured":"Savarese G, Becher PM, Lund LH, Seferovic P, Rosano GM, Coats AJ. Global burden of heart failure: a comprehensive and updated review of epidemiology. Cardiovasc Res. 2023, 118:3272-87. 10.1093\/cvr\/cvac013","journal-title":"Cardiovasc Res"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacasi.2024.01.013","article-title":"Epidemiology and burden of\u00a0heart\u00a0failure in Asia","volume":"4","author":"Feng J","year":"2024","unstructured":"Feng J, Zhang Y, Zhang J. Epidemiology and burden of\u00a0heart\u00a0failure in Asia. JACC Asia. 2024, 4:249-64. 10.1016\/j.jacasi.2024.01.013","journal-title":"JACC Asia"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.283","article-title":"Clinical presentation, management, in-hospital and 90-day outcomes of heart failure patients in Trivandrum, Kerala, India: the Trivandrum Heart Failure Registry","volume":"17","author":"Harikrishnan S","year":"2015","unstructured":"Harikrishnan S, Sanjay G, Anees T, et al.. Clinical presentation, management, in-hospital and 90-day outcomes of heart failure patients in Trivandrum, Kerala, India: the Trivandrum Heart Failure Registry. Eur J Heart Fail. 2015, 17:794-800. 10.1002\/ejhf.283","journal-title":"Eur J Heart Fail"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.ihj.2019.07.008","article-title":"Clinical profile and one-year survival of patients with heart failure with reduced ejection fraction: the largest report from India","volume":"71","author":"Chopra VK","year":"2019","unstructured":"Chopra VK, Mittal S, Bansal M, Singh B, Trehan N. Clinical profile and one-year survival of patients with heart failure with reduced ejection fraction: the largest report from India. Indian Heart J. 2019, 71:242-8. 10.1016\/j.ihj.2019.07.008","journal-title":"Indian Heart J"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehab793","article-title":"The Cardiology Society of India-Kerala Acute Heart Failure Registry: poor adherence to guideline-directed medical therapy","author":"Joseph S","year":"2021","unstructured":"Joseph S, Panniyammakal J, Abdullakutty J, et al.. The Cardiology Society of India-Kerala Acute Heart Failure Registry: poor adherence to guideline-directed medical therapy. Eur Heart J. 2021, ehab793. 10.1093\/eurheartj\/ehab793","journal-title":"Eur Heart J"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2022.03.021","article-title":"Clinical characteristics and 30-day outcomes in patients with acute decompensated heart failure: results from Indian College of Cardiology National Heart Failure Registry (ICCNHFR)","volume":"356","author":"Jayagopal PB","year":"2022","unstructured":"Jayagopal PB, Sastry SL, Nanjappa V, et al.. Clinical characteristics and 30-day outcomes in patients with acute decompensated heart failure: results from Indian College of Cardiology National Heart Failure Registry (ICCNHFR). Int J Cardiol. 2022, 356:73-8. 10.1016\/j.ijcard.2022.03.021","journal-title":"Int J Cardiol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30748-0","article-title":"Estimating lifetime benefits of comprehensive disease-modifying pharmacological therapies in patients with heart failure with reduced ejection fraction: a comparative analysis of three randomised controlled trials","volume":"396","author":"Vaduganathan M","year":"2020","unstructured":"Vaduganathan M, Claggett BL, Jhund PS, et al.. Estimating lifetime benefits of comprehensive disease-modifying pharmacological therapies in patients with heart failure with reduced ejection fraction: a comparative analysis of three randomised controlled trials. Lancet. 2020, 396:121-8. 10.1016\/S0140-6736(20)30748-0","journal-title":"Lancet"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.cardfail.2022.07.047","article-title":"Guideline-directed medical therapy in newly diagnosed heart failure with reduced ejection fraction in the community","volume":"28","author":"Dunlay SM","year":"2022","unstructured":"Dunlay SM, Killian JM, Roger VL, Schulte PJ, Blecker SB, Savitz ST, Redfield MM. Guideline-directed medical therapy in newly diagnosed heart failure with reduced ejection fraction in the community. J Card Fail. 2022, 28:1500-8. 10.1016\/j.cardfail.2022.07.047","journal-title":"J Card Fail"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1161\/01.cir.0000035653.72855.bf","article-title":"Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) study","volume":"106","author":"Packer M","year":"2002","unstructured":"Packer M, Fowler MB, Roecker EB, et al.. Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) study. Circulation. 2002, 106:2194-9. 10.1161\/01.cir.0000035653.72855.bf","journal-title":"Circulation"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin-neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray JJ","year":"2014","unstructured":"McMurray JJ, Packer M, Desai AS, et al.. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014, 371:993-1004. 10.1056\/NEJMoa1409077","journal-title":"N Engl J Med"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray JJ","year":"2019","unstructured":"McMurray JJ, Solomon SD, Inzucchi SE, et al.. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019, 381:1995-2008. 10.1056\/NEJMoa1911303","journal-title":"N Engl J Med"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2021.12.012","article-title":"2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"79","author":"Heidenreich PA","year":"2022","unstructured":"Heidenreich PA, Bozkurt B, Aguilar D, et al.. 2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2022, 79:e263-421. 10.1016\/j.jacc.2021.12.012","journal-title":"J Am Coll Cardiol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2017.04.010","article-title":"Change the management of patients with heart failure: rationale and design of the CHAMP-HF Registry","volume":"189","author":"DeVore AD","year":"2017","unstructured":"DeVore AD, Thomas L, Albert NM, et al.. Change the management of patients with heart failure: rationale and design of the CHAMP-HF Registry. Am Heart J. 2017, 189:177-83. 10.1016\/j.ahj.2017.04.010","journal-title":"Am Heart J"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2020.10.012","article-title":"Five-year mortality and readmission rates in patients with heart failure in India: results from the Trivandrum Heart Failure Registry","volume":"326","author":"Harikrishnan S","year":"2021","unstructured":"Harikrishnan S, Jeemon P, Ganapathi S, et al.. Five-year mortality and readmission rates in patients with heart failure in India: results from the Trivandrum Heart Failure Registry. Int J Cardiol. 2021, 326:139-43. 10.1016\/j.ijcard.2020.10.012","journal-title":"Int J Cardiol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2021.754499","article-title":"Sacubitril-valsartan, clinical benefits and related mechanisms of action in heart failure with reduced ejection fraction. A review","volume":"8","author":"Pascual-Figal D","year":"2021","unstructured":"Pascual-Figal D, Bay\u00e9s-Genis A, Beltr\u00e1n-Troncoso P, et al.. Sacubitril-valsartan, clinical benefits and related mechanisms of action in heart failure with reduced ejection fraction. A review. Front Cardiovasc Med. 2021, 8:754499. 10.3389\/fcvm.2021.754499","journal-title":"Front Cardiovasc Med"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1097\/FJC.0000000000000641","article-title":"Sacubitril\/valsartan in daily clinical practice: data from a prospective registry","volume":"73","author":"Vicent L","year":"2019","unstructured":"Vicent L, Esteban-Fern\u00e1ndez A, G\u00f3mez-Bueno M, et al.. Sacubitril\/valsartan in daily clinical practice: data from a prospective registry. J Cardiovasc Pharmacol. 2019, 73:118-24. 10.1097\/FJC.0000000000000641","journal-title":"J Cardiovasc Pharmacol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1097\/FJC.0000000000000643","article-title":"Titration and tolerability of sacubitril\/valsartan for patients with heart failure in clinical practice","volume":"73","author":"Du AX","year":"2019","unstructured":"Du AX, Westerhout CM, McAlister FA, et al.. Titration and tolerability of sacubitril\/valsartan for patients with heart failure in clinical practice. J Cardiovasc Pharmacol. 2019, 73:149-54. 10.1097\/FJC.0000000000000643","journal-title":"J Cardiovasc Pharmacol"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehw128","article-title":"2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)","volume":"37","author":"Ponikowski P","year":"2016","unstructured":"Ponikowski P, Voors AA, Anker SD, et al.. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Eur Heart J. 2016, 37:2129-200. 10.1093\/eurheartj\/ehw128","journal-title":"Eur Heart J"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016\/j.cegh.2024.101556","article-title":"Unveiling the impact of an Indian-specific heart failure checklist on heart failure with reduced ejection fraction management in the South Indian population","volume":"27","author":"Philip A","year":"2024","unstructured":"Philip A, Shastry CS, Utagi B, Alex A. Unveiling the impact of an Indian-specific heart failure checklist on heart failure with reduced ejection fraction management in the South Indian population. Clin Epidemiol Glob Health. 2024, 27:101556. 10.1016\/j.cegh.2024.101556","journal-title":"Clin Epidemiol Glob Health"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1002\/clc.22519","article-title":"Guideline-directed medication use in patients with heart failure with reduced ejection fraction in India: American College of Cardiology's PINNACLE India Quality Improvement Program","volume":"39","author":"Pokharel Y","year":"2016","unstructured":"Pokharel Y, Wei J, Hira RS, et al.. Guideline-directed medication use in patients with heart failure with reduced ejection fraction in India: American College of Cardiology's PINNACLE India Quality Improvement Program. Clin Cardiol. 2016, 39:145-9. 10.1002\/clc.22519","journal-title":"Clin Cardiol"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.10262","article-title":"Heart failure with reduced ejection fraction: a review","volume":"324","author":"Murphy SP","year":"2020","unstructured":"Murphy SP, Ibrahim NE, Januzzi JL Jr. Heart failure with reduced ejection fraction: a review. JAMA. 2020, 324:488-504. 10.1001\/jama.2020.10262","journal-title":"JAMA"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcha.2022.101159","article-title":"Outcomes and predictors of one-year mortality in patients hospitalized with acute heart failure","volume":"43","author":"Lorlowhakarn K","year":"2022","unstructured":"Lorlowhakarn K, Arayakarnkul S, Trongtorsak A, et al.. Outcomes and predictors of one-year mortality in patients hospitalized with acute heart failure. Int J Cardiol Heart Vasc. 2022, 43:101159. 10.1016\/j.ijcha.2022.101159","journal-title":"Int J Cardiol Heart Vasc"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.6515\/acs20170202a","article-title":"One-year outcomes of acute decompensated systolic heart failure in Taiwan: lessons from TSOC-HFrEF Registry","volume":"33","author":"Chang HY","year":"2017","unstructured":"Chang HY, Wang CC, Wu YW, et al.. One-year outcomes of acute decompensated systolic heart failure in Taiwan: lessons from TSOC-HFrEF Registry. Acta Cardiol Sin. 2017, 33:127-38. 10.6515\/acs20170202a","journal-title":"Acta Cardiol Sin"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.119.012199","article-title":"Regional variation of mortality in heart failure with reduced and preserved ejection fraction across Asia: outcomes in the ASIAN-HF Registry","volume":"9","author":"MacDonald MR","year":"2020","unstructured":"MacDonald MR, Tay WT, Teng TK, et al.. Regional variation of mortality in heart failure with reduced and preserved ejection fraction across Asia: outcomes in the ASIAN-HF Registry. J Am Heart Assoc. 2020, 9:e012199. 10.1161\/JAHA.119.012199","journal-title":"J Am Heart Assoc"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.4070\/kcj.2016.0419","article-title":"Clinical characteristics and outcome of acute heart failure in Korea: results from the Korean Acute Heart Failure Registry (KorAHF)","volume":"47","author":"Lee SE","year":"2017","unstructured":"Lee SE, Lee HY, Cho HJ, et al.. Clinical characteristics and outcome of acute heart failure in Korea: results from the Korean Acute Heart Failure Registry (KorAHF). Korean Circ J. 2017, 47:341-53. 10.4070\/kcj.2016.0419","journal-title":"Korean Circ J"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1002\/ehf2.13237","article-title":"Patient factors associated with titration of medical therapy in patients with heart failure with reduced ejection fraction: data from the QUALIFY International Registry","volume":"8","author":"Cowie MR","year":"2021","unstructured":"Cowie MR, Sch\u00f6pe J, Wagenpfeil S, et al.. Patient factors associated with titration of medical therapy in patients with heart failure with reduced ejection fraction: data from the QUALIFY International Registry. ESC Heart Fail. 2021, 8:861-71. 10.1002\/ehf2.13237","journal-title":"ESC Heart Fail"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.2644","article-title":"Trajectories in New York Heart Association functional class in heart failure across the ejection fraction spectrum: data from the Swedish Heart Failure Registry","volume":"24","author":"Lindberg F","year":"2022","unstructured":"Lindberg F, Lund LH, Benson L, et al.. Trajectories in New York Heart Association functional class in heart failure across the ejection fraction spectrum: data from the Swedish Heart Failure Registry. Eur J Heart Fail. 2022, 24:2093-104. 10.1002\/ejhf.2644","journal-title":"Eur J Heart Fail"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1136\/heartjnl-2018-314173","article-title":"Prognosis and NT-proBNP in heart failure patients with preserved versus reduced ejection fraction","volume":"105","author":"Salah K","year":"2019","unstructured":"Salah K, Stienen S, Pinto YM, et al.. Prognosis and NT-proBNP in heart failure patients with preserved versus reduced ejection fraction. Heart. 2019, 105:1182-9. 10.1136\/heartjnl-2018-314173","journal-title":"Heart"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1016\/j.ihj.2020.09.016","article-title":"Efficacy and safety of sacubitril\/valsartan compared with enalapril in patients with chronic heart failure and reduced ejection fraction: results from PARADIGM-HF India sub-study","volume":"72","author":"Jain AR","year":"2020","unstructured":"Jain AR, Aggarwal RK, Rao NS, Billa G, Kumar S. Efficacy and safety of sacubitril\/valsartan compared with enalapril in patients with chronic heart failure and reduced ejection fraction: results from PARADIGM-HF India sub-study. Indian Heart J. 2020, 72:535-40. 10.1016\/j.ihj.2020.09.016","journal-title":"Indian Heart J"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.11622\/smedj.2021092","article-title":"Angiotensin receptor-neprilysin inhibitor improves New York Heart Association class and N-terminal-pro B-type natriuretic peptide levels: initial experience in a Singapore single-centre cohort","volume":"62","author":"Koh N","year":"2021","unstructured":"Koh N, Goh VJ, Teoh CK, Hon JS, Teo LL, Lim CP, Sim D. Angiotensin receptor-neprilysin inhibitor improves New York Heart Association class and N-terminal-pro B-type natriuretic peptide levels: initial experience in a Singapore single-centre cohort. Singapore Med J. 2021, 62:359-61. 10.11622\/smedj.2021092","journal-title":"Singapore Med J"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2019.12821","article-title":"Association of change in N-terminal pro-B-type natriuretic peptide following initiation of sacubitril-valsartan treatment with cardiac structure and function in patients with heart failure with reduced ejection fraction","volume":"322","author":"Januzzi JL Jr","year":"2019","unstructured":"Januzzi JL Jr, Prescott MF, Butler J, et al.. Association of change in N-terminal pro-B-type natriuretic peptide following initiation of sacubitril-valsartan treatment with cardiac structure and function in patients with heart failure with reduced ejection fraction. JAMA. 2019, 322:1085-95. 10.1001\/jama.2019.12821","journal-title":"JAMA"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000035589","article-title":"Long-term effects of angiotensin receptor neprilysin inhibitor therapy in heart failure patients with reduced ejection fraction: a retrospective cohort study","volume":"102","author":"Ko\u00e7ak A","year":"2023","unstructured":"Ko\u00e7ak A, Aydin S, Aliba\u015fi\u00e7 H, \u00c7i\u00e7ek M, Ekici B. Long-term effects of angiotensin receptor neprilysin inhibitor therapy in heart failure patients with reduced ejection fraction: a retrospective cohort study. Medicine (Baltimore). 2023, 102:e35589. 10.1097\/MD.0000000000035589","journal-title":"Medicine (Baltimore)"},{"key":"ref37","unstructured":"Sacubitril\/\u200bvalsartan in heart failure with reduced ejection fraction patients. a real world study in India. (2023). Accessed: June 1, 2025: https:\/\/www.clinicaltrials.gov\/study\/NCT04735354?cond=Sacubitril%2FValsartan&page=2&rank=43."}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/365994-real-world-evaluation-of-the-dosage-patterns-and-safety-of-angiotensin-receptor-neprilysin-inhibitor-therapy-in-indian-patients-with-heart-failure-with-reduced-ejection-fraction-the-add-arni-study-protocol","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,16]],"date-time":"2025-07-16T04:14:30Z","timestamp":1752639270000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/365994-real-world-evaluation-of-the-dosage-patterns-and-safety-of-angiotensin-receptor-neprilysin-inhibitor-therapy-in-indian-patients-with-heart-failure-with-reduced-ejection-fraction-the-add-arni-study-protocol"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,15]]},"references-count":37,"URL":"https:\/\/doi.org\/10.7759\/cureus.88037","relation":{},"ISSN":["2168-8184"],"issn-type":[{"type":"print","value":"2168-8184"}],"subject":[],"published":{"date-parts":[[2025,7,15]]}}}